The American Journal of Medicine
Volume 122, Issue 4 , Pages 322-328 , April 2009

Renal Effects of Anti-angiogenesis Therapy: Update for the Internist

  • Faina Gurevich, MD

      Affiliations

    • Department of Medicine, Yale University School of Medicine, New Haven, Conn
    • ,
  • Mark A. Perazella, MD

      Affiliations

    • Section of Nephrology, Department of Medicine, Yale University School of Medicine, New Haven, Conn
    • Corresponding Author InformationRequests for reprints should be addressed to Mark A. Perazella, MD, Section of Nephrology, Department of Medicine, Yale University School of Medicine, FMP 107, 330 Cedar Street, New Haven, CT 06520-8029

References 

  1. Folkman J. Tumor angiogenesis (Therapeutic implications). N Engl J Med. 1971;285:1182–1186
  2. Izzedine H, Rixe O, Billemont B, et al. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis. 2007;50(2):203–218
  3. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999;77:527–543
  4. Maharaj ASR, Saint-Geniez M, Maldonado AE, D'Amore P. Vascular endothelial growth factor localization in the adult. Am J Pathol. 2006;168(2):639–648
  5. Esser S, Wolburg K, Wolburg H, et al. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol. 1998;140(4):947–959
  6. Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist. 2000;5(Suppl 1):20–27
  7. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician. 2008;77(3):311–319
  8. Lin YS, Nguyen C, Mendoza JL, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther. 1999;288(1):371–378
  9. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–2676
  10. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342
  11. Yang JC, Haworth L, Sherry R, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–434
  12. Sandler A, Gray R, Perry M, et al. Paclitaxel-carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med. 2006;355:2542–2550
  13. Emmanouilides C, Sfakiotaki G, Androulakis N, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer. 2007;7:91
  14. Rudge JS, Holash J, Hylton D, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A. 2007;104(47):18363–18370
  15. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–124
  16. Escudier B, Eisen T, Stadler WM, et al. TARGET Study Group Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–134
  17. Lameire NH, Flombaum CD, Moreau D, Ronco C. Acute renal failure in cancer patients. Ann Med. 2005;37(1):13–25
  18. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab. J Clin Oncol. 2004;22(14S):3702;2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
  19. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006;24:1363–1369
  20. Zhu X, Wu S, Dahut W, et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49:186–193
  21. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol. 2008;27:1–9
  22. Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in cancer patients. Lancet Oncol. 2008;9:117–123
  23. Hood JD, Meininger CJ, Ziche M, et al. VEGF upregulates eNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998;274:H1054–H1058
  24. Shen BQ, Lee DY, Zioncheck TF. Vascular endothelial growth factor governs nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem. 1999;274:33057–33063
  25. Zou AP, Cowley AW. Role of nitric oxide in the control of renal function and salt sensitivity. Curr Hypertens Rep. 1999;1(2):178–186
  26. Feihl F, Liaudet L, Waeber B, Levy BI. Hypertension (A disease of the microcirculation?). Hypertension. 2006;48:1012–1017
  27. Struyker-Boudier HA, le Noble JL, Slaaf DW, et al. Microcirculatory changes in cremaster muscle during early spontaneous hypertension in the rat. J Hypertens Suppl. 1988;6(4):S185–S187
  28. Harper RN, Moore MA, Marr MC, et al. Arteriolar rarefaction in the conjunctiva of human essential hypertensives. Microvasc Res. 1978;16:369–372
  29. Castilla MA, Caramelo C, Gazapo RM, et al. Role of vascular endothelial growth factor (VEGF) in endothelial cell protection against cytotoxic agents. Life Sci. 2000;67:1003–1013
  30. Gonzalez-Pacheco FR, Deudero JJ, Castellanos MC, et al. Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2. Am J Physiol Heart Circ Physiol. 2006;291:H1395–H1401
  31. Pande A, Lombardo J, Spangenthal E, Javle M. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res. 2007;27(5B):3465–3470
  32. Patel TV, Morgan JA, Demetri GD, et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst. 2008;100(4):282–284
  33. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003;278(15):12605–12608
  34. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788–1795
  35. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792–799
  36. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol. 2004;22:2184–2191
  37. George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis. 2007;49:23–29
  38. Eremina V, Jefferson A, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129–1136
  39. Izzedine H, Rixe O, Brocheriou I, Deray G. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant. 2007;22:1481–1482
  40. Roncone D, Satoskar A, Nadasdy T, Monk JP, Rovin BH. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol. 2007;3:287–293
  41. Frangie C, Lefaucheur C, Medioni J, et al. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol. 2007;8(2):177–178
  42. Hara A, Wada T, Furuichi K, et al. Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int. 2006;69(11):1986–1995
  43. Barakat RK, Singh N, Lal R, et al. Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma. Ann Pharmacother. 2007;41(4):707–710

 Funding: None.

 Conflicts of Interest: None.

 Authorship: Both authors contributed equally to writing the manuscript.

PII: S0002-9343(09)00006-0

doi: 10.1016/j.amjmed.2008.11.025

The American Journal of Medicine
Volume 122, Issue 4 , Pages 322-328 , April 2009

Article Tools

* Image Usage & Resolution